ATNM — Actinium Pharmaceuticals, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1388320 ·
Last close
$1.18
Market Cap
$37.10M
52W High
$1.74
52W Low
$0.74
ADV30
146,068
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 35,000,000 | — | 27,565,000 | 27,901,000 | 40,157,000 | 36,473,000 | 9,855,000 |
| Mar 2026 | 0 | — | -5,903,000 | -5,522,000 | 45,438,000 | 42,132,000 | 43,134,000 |
| Dec 2025 | 0 | — | -6,414,000 | -5,940,000 | 51,775,000 | 47,998,000 | 43,941,000 |
| Sep 2025 | 90,000 | — | -5,692,000 | -5,131,000 | 56,151,000 | 53,391,000 | 42,367,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-22,876,000
Investing CF
$-106,000
Financing CF
$-218,000
CapEx
$-2,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.07
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-415,235,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-25,512,000
Pretax Income TTM
$-23,471,000
Interest Exp TTM
—
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,090,000
EBITDA
$9,791,000
Free Cash Flow
$7,143,500
Enterprise Value
$8,886,010
Total Cash
$36,473,000
Total Debt
$1,341,000
Shares Out
31,441,436
Trailing EPS
$0.35
Book Value
$0.96
ROE
45.9%
ROA
11.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 90,000 | -36,247,000 | -33,887,000 | 51,775,000 | 43,941,000 | 7,834,000 | -24,580,000 |
| Dec 2024 | 0 | -42,121,000 | -38,243,000 | 76,899,000 | 44,141,000 | 32,758,000 | -33,072,000 |
| Dec 2023 | 81,000 | -51,920,000 | -48,818,000 | 81,445,000 | 45,066,000 | 36,379,000 | -47,335,000 |
| Dec 2022 | 1,030,000 | -34,104,000 | -33,017,000 | 114,192,000 | 47,711,000 | 66,481,000 | 8,644,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-0.53
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| MTNB | Matinas BioPharma Holdings, Inc. | $37.17M | $2.53 | — |
| KPTI | Karyopharm Therapeutics Inc. | $36.74M | $1.62 | — |
| BETRF | BetterLife Pharma Inc. | $37.95M | $0.22 | — |
| MIRA | MIRA PHARMACEUTICALS, INC. | $37.96M | $0.90 | — |
| BCTX | BriaCell Therapeutics Corp. | $36.15M | $4.16 | — |
News headlines (Yahoo Finance, 1h cache)
ATNM: Initiating Coverage – Diversified Nuclear Medicine Portfolio
2026-09-15 09:08 · Yahoo
Actinium Pharmaceuticals, Inc. to Present at the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-04 21:05 · Yahoo
Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
2026-08-14 21:02 · Yahoo
Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Pros
2026-06-03 11:25 · Yahoo
Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development
2026-06-01 12:00 · Yahoo
Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice
2026-05-29 21:30 · Yahoo
Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization
2026-05-06 12:00 · Yahoo
Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer
2026-04-22 11:00 · Yahoo
Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting
2026-04-06 11:30 · Yahoo
Hematopoietic Stem Cell Transplantation Market Landscape to Evolve at a CAGR of 12.4% During the Forecast Period (2026-2036) as Novel Therapies and Expanding Patient Eligibility Drive Growth | DelveIn
2026-06-22 14:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.